Loading…

The morning briefing, in your inbox.

Top Cyprus + world stories, summarised. Every day.

Developed by Muflon

UNI-PHARMA plans innovative Research and Innovation Center for monoclonal antibody development · Cyprus Report

Health · Greece

UNI-PHARMA plans innovative Research and Innovation Center for monoclonal antibody development

1 sourceFirst reported 21 days agoUpdated 21 days ago

AI summary: catch up in 20 seconds

UNI-PHARMA has submitted an investment proposal for a new Research and Innovation Center focused on the development of monoclonal antibodies.
The proposal has been made through Enterprise Greece, aimed at enhancing the pharmaceutical industry's capabilities.
This initiative seeks to position UNI-PHARMA at the forefront of advanced therapeutic research.
Details regarding the timeline and specific funding for the center have not been disclosed.
The establishment of this center reflects ongoing efforts to innovate within the pharmaceutical sector in Greece.

Generated by AI from the 1 sources below · always verify with the originals

AI summary: catch up in 20 seconds

Summarising the coverage…

Generated by AI from the 1 sources below · always verify with the originals

All coverage (1)

UNI-PHARMA: Ετοιμάζει πρωτότυπο Κέντρο Έρευνας & Καινοτομίας για την Ανάπτυξη Μονοκλωνικών ΑντισωμάτωνNaftemporiki · 21 days ago

No comments yet. Be the first to join the discussion.

AI summary: catch up in 20 seconds

UNI-PHARMA has submitted an investment proposal for a new Research and Innovation Center focused on the development of monoclonal antibodies.
The proposal has been made through Enterprise Greece, aimed at enhancing the pharmaceutical industry's capabilities.
This initiative seeks to position UNI-PHARMA at the forefront of advanced therapeutic research.
Details regarding the timeline and specific funding for the center have not been disclosed.
The establishment of this center reflects ongoing efforts to innovate within the pharmaceutical sector in Greece.

Generated by AI from the 1 sources below · always verify with the originals